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ABSTRACT

Background We describe the early experiences of
adults with systemic rheumatic disease who received the
COVID-19 vaccine.
Methods From 2 April to 30 April 2021, we conducted
an online, international survey of adults with systemic
rheumatic disease who received COVID-19 vaccination.
We collected patient-reported data on clinician
communication, beliefs and intent about discontinuing
disease-modifying antirheumatic drugs (DMARDs) around
the time of vaccination, and patient-reported adverse
events after vaccination.
Results We analysed 2860 adults with systemic
rheumatic diseases who received COVID-19 vaccination
(mean age 55.3 years, 86.7% female, 86.3% white). Types
of COVID-19 vaccines were Pfizer-BioNTech (53.2%),
Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/
Johnson & Johnson (1.7%) and others (1.2%). The most
common rheumatic disease was rheumatoid arthritis
(42.3%), and 81.2% of respondents were on a DMARD.
The majority (81.9%) reported communicating with
clinicians about vaccination. Most (66.9%) were willing
to temporarily discontinue DMARDs to improve vaccine
efficacy, although many (44.3%) were concerned about
rheumatic disease flares. After vaccination, the most
reported patient-reported adverse events were fatigue/
somnolence (33.4%), headache (27.7%), muscle/joint

Key messages
What is already known about this subject?
►► People with systemic rheumatic diseases, who

were largely excluded from COVID-19 vaccine
clinical trials, may have additional concerns
about the impact of their underlying disease or
antirheumatic medications on COVID-19 vaccine
response.
►► Studies of rheumatic disease flares following
vaccination for other infections were previously
reassuring, and studies from a physician-based
registry and a prospective cohort have shown
a low frequency of flares following COVID-19
vaccination.

What does this study add?
►► In this international online survey of adults

with systemic rheumatic disease who received
COVID-19 vaccination, patient-reported adverse
events were typical of those reported in the general population, with rheumatic disease flare requiring medication changes occurring in <5%.
►► Most patients were willing to temporarily discontinue disease-modifying antirheumatic drugs in
order to improve vaccine efficacy.
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Key messages
How might this impact on clinical practice or further
developments?
►► Clinicians should maintain awareness of changing guidelines as

further data become available in order to provide continued communication and patient counselling regarding risks and benefits of
vaccination.
pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that
required medication changes occurred in 4.6%.
Conclusion Among adults with systemic rheumatic disease who
received COVID-19 vaccination, patient-reported adverse events were
typical of those reported in the general population. Most patients were
willing to temporarily discontinue DMARDs to improve vaccine efficacy.
The relatively low frequency of rheumatic disease flare requiring
medications was reassuring.

INTRODUCTION
Multiple COVID-19 vaccines have become available, with
established safety and efficacy in the general population.1
However, people with systemic rheumatic diseases, who
may have a unique risk and benefit profile, were largely
excluded from the initial vaccine clinical trials. People
with systemic rheumatic diseases may have specific
concerns on how their underlying disease or their immunomodulatory therapies affect the benefit and safety of
receiving COVID-19 vaccination.2 3 These concerns have
been further complicated by heterogenous vaccine rollouts and access, and conflicting advice from clinicians
in response to major organisation recommendations.4–6
There is a paucity of data regarding vaccinated patients
with rheumatic diseases, and better information could
inform decision making and guidance for clinicians
and patients. This study describes a large, international
survey of adults with systemic rheumatic disease who
received a COVID-19 vaccine, focusing on their experiences communicating with clinicians, their beliefs about
and management of medications for their rheumatic
disease around the time of vaccination, and their experience with adverse events after vaccination.
METHODS
Survey design and inclusion
The COVID-19 Global Rheumatology Alliance (C19-GRA)
Vaccine Survey was developed and refined based on feedback from relevant stakeholders (clinicians, researchers
and patient partners) and collaborators from December
2020 through March 2021. The survey collected information from both COVID-19 vaccinated and unvaccinated
adults with systemic rheumatic diseases.
To study a more homogenous group and to obtain a
better understanding of characteristics and factors associated with vaccination, this analysis was restricted to
adults with systemic rheumatic diseases who received
COVID-19 vaccination. Respondents were included if
2

they completed the survey in English, Italian or Hebrew
(first translations made available) between 2 April and 30
April 2021 and reported having received at least one dose
of any COVID-19 vaccine. Respondents were excluded if
they did not provide information on the following characteristics: age, sex, country of residence, race/ethnicity,
rheumatic disease diagnosis and use of antirheumatic
medications. Respondents reporting only diagnoses of
osteoarthritis and/or only fibromyalgia without other
systemic rheumatic diseases were also excluded.
The survey was administered online using the Qualtrics
platform, an online survey software that allows for the
creation and distribution of surveys and other measurement tools. After providing initial consent to participate, respondents were required to enter their year of
birth and only received additional questions if they were
over the age of 18 years. Where possible, participants
were required to enter a response to questions before
proceeding in order to minimise missing responses. Also,
Internet Protocol address gating, restricting only one
survey entry per individual (or source), was employed in
order to secure integrity of responses and data.
Measures and data collection
Demographics
Self-
reported demographics including year of birth
(from which age was calculated), sex assigned at birth,
highest level of education, current employment and
country of residence were collected. Country of residence was grouped by the WHO region.7 Race/Ethnicity
was grouped into mutually exclusive categories: black,
Asian (including East Asian, South Asian and West
Asian), Hispanic, Latinx or Latin American, white, American Indian/Alaska Natives/Aboriginal/Indigenous/
First Nations, Arab, Pacific Islander and multiple identities (ie, participants reporting more than one race/
ethnicity).
Systemic rheumatic disease diagnosis and clinical information
Participants could report multiple systemic rheumatic
disease diagnoses. Comorbidities were also collected
and included over 30 possible selections. Patient global
assessment of current rheumatic disease activity was self-
reported using a patient global assessment of disease
activity visual analogue scale from 0 (remission/very low
disease activity) to 10 (very high disease activity).8
Disease-modifying antirheumatic drug, glucocorticoid and nonsteroidal anti-inflammatory drug use
Participants reported the disease-
modifying antirheumatic drugs (DMARDs), glucocorticoids and non-
steroidal anti-
inflammatory drugs (NSAIDs) that they
were taking at the time of the survey. Medications were
grouped into different classes according to mechanism
of action, with a free text option to report additional
medications. Free text was categorised into appropriate
medication classes after translation.
Sattui SE, et al. RMD Open 2021;7:e001814. doi:10.1136/rmdopen-2021-001814

RMD Open: first published as 10.1136/rmdopen-2021-001814 on 7 September 2021. Downloaded from http://rmdopen.bmj.com/ on December 29, 2021 at Washington University School of
Medicine Library &. Protected by copyright.

RMD Open

DMARDs were categorised using the most recent
American College of Rheumatology (ACR) COVID-19
Vaccine Clinical Guidance Summary.6 Medications,
where holding or altered dosage timing around time of
vaccination was recommended (methotrexate, abatacept,
rituximab, Janus kinase (JAK) inhibitors) were grouped
independently.
Communication with clinicians and medication changes
Participants were asked about vaccine-related communication and counselling by their clinicians. All survey
respondents were asked about their general willingness to temporarily discontinue medications based on a
5-point Likert scale. In addition, for each specific medication that participants reported taking, they were asked
if they would be willing to discontinue those medications (yes/no/unsure), to improve the effectiveness of
a COVID-19 vaccine. They were also asked about their
greatest concern(s) about temporarily discontinuing
those medications. Finally, participants were asked if they
held any medications before or after vaccination (yes/
no/unsure).
Adverse events after vaccination
In addition to self-reported anaphylaxis, participants were
asked about the occurrence of postvaccination adverse
events, lasting >2 days and within 2 months of vaccination,
such as headaches, fever or chills, widespread muscle/
joint pain and rash, among others. Respondents also
reported whether they experienced postvaccine flares of
existing systemic rheumatic disease (lasting >2 days) and
if these flares required treatment modifications.
Survey dissemination
The English language version of the survey was launched
globally on 2 April 2021. Translations in Italian and
Hebrew were added on 5 April 2021. We employed a
convenience sampling strategy with patient partners
leading survey dissemination. International patient
organisations received images, text and survey links
designed to explain the survey’s purpose, and disseminated the survey to their members. Additionally, the
survey was publicly accessible from the C19-GRA website (
www.rheum-covid.org) and disseminated via social media
by GRA members and patient organisations. The full
survey is included in the online supplemental materials.
Statistical analysis
Descriptive statistics, including means and SD, proportions and 95% CIs, were reported. All analyses were
performed using R V.4.1.0.
RESULTS
Demographics and clinical characteristics
Between 2 April and 30 April 2021, 2860 adults with
systemic rheumatic disease who received at least one
dose of a COVID-19 vaccine participated in the survey
(see figure 1 for flow diagram of analysed sample). The
Sattui SE, et al. RMD Open 2021;7:e001814. doi:10.1136/rmdopen-2021-001814

Figure 1 Flow diagram illustrating the analysed sample.

mean (SD) age of participants was 55.3 (14.3) years, 2480
(86.7%) were female and 2469 (86.3%) self-identified
as white. Most participants (1603, 56.1%) were from
the Americas (USA n=1366, Canada n=200 and Latin
America n=37), followed by respondents from the European region (UK n=935, and rest of Europe n=252).
Demographics and clinical characteristics of respondents
are shown in table 1.
Rheumatoid arthritis (RA) (1209, 42.3%) was the most
common systemic rheumatic disease reported among
participants, followed by inflammatory myositis (487,
17.0%), Sjögren’s syndrome (438, 15.3%), systemic
lupus erythematosus (391, 13.7%) and spondyloarthritis
(256, 9.0%). Use of systemic glucocorticoids and NSAIDs
was reported by 762 (26.6%) and 740 (25.9%), respectively. The most used DMARDs were methotrexate (855,
29.9%), antimalarials (733, 25.6%) and other conventional synthetic DMARDs (510, 17.8%). Tumour necrosis
factor (TNF) inhibitors were the most used biologic
DMARD (bDMARD) (493, 17.2%), and 520 (18.2%) of
patients reported not taking any DMARD.
The most reported comorbidities were hypertension
(912, 31.9%), lung disease (736, 25.7%) and obesity
(673, 23.5%). The most received COVID-19 vaccine was
BioNTech vaccine (1522, 53.2%), followed
the Pfizer-
AstraZeneca (645, 22.6%), Moderna (610,
by Oxford-
21.3%) and Janssen/Johnson & Johnson (50, 1.7%). Few
respondents received other vaccines (33, 1.2%).
Communication with healthcare providers regarding
COVID-19 vaccination
Most participants (2341, 81.9%) had discussed COVID-19
vaccination with their healthcare provider. Participants
3
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Table 1 Demographics and clinical characteristics of
the COVID-19 Global Rheumatology Vaccine Survey
respondents who received COVID-19 vaccination (n=2860)
Number of
respondents N (%)
Age (years), mean (SD)

55.3 (14.3)

Age (years) categories
 18–29

139 (4.9)

 30–49

788 (27.6)

 50–69

1336 (46.7)

 70+

469 (16.4)

Sex at birth
 Female
 Male
 Other/Prefer not to say

2480 (86.7)
373 (13.0)
7 (0.2)

Race/Ethnicity
 White

2469 (86.3)

 Hispanic, Latinx or Latin American

77 (2.7)

 Asian (South, East Asian)

46 (1.6)

 Black

37 (1.3)

 Middle Eastern or North African

21 (0.7)

 American Indian/laska Natives/Aboriginal/
Indigenous/First Nations
 Other*

7 (0.2)
203 (7.1)

WHO region
 Region of the Americas

1603 (56.1)

 European region

1187 (41.5)

 Western Pacific/South-East Asian/African/
Eastern Mediterranean regions

70 (2.4)

Educational level

Table 1

Continued
Number of
respondents N (%)

 Antimalarials

733 (25.6)

 Methotrexate

855 (29.9)

 Other csDMARDs§

513 (17.8)

 Mycophenolate mofetil

228 (8.0)

 Other antimetabolites¶

21 (0.7)

 Abatacept

71 (2.5)

 Rituximab

162 (5.7)

 TNF inhibitors

498 (17.2)

 Other bDMARDs**

206 (7.2)

 JAK inhibitors

121 (4.2)

 IVIG

102 (3.6)

Number of DMARDs
 0

520 (18.2)

 1

1271 (44.4)

 2

839 (29.3)

 3 or more

230 (8.0)

Patient global assessment of disease activity
(0=very low; 10=very high)
 Mean (SD)

4.2 (2.4)

Comorbidities
 Hypertension

912 (31.9)

 Lung disease††

736 (25.7)

 Obesity

672 (23.5)

 Diabetes

164 (5.7)

 Cardiovascular disease

163 (5.7)

 None

832 (29.1)

COVID-19 vaccine received

 High school (secondary level)/General
Educational Development (GED) or less

314 (11.0)

 Some college

553 (19.3)

 Oxford-AstraZeneca

645 (22.6)

 Bachelor’s degree (graduated college)

776 (27.1)

 Moderna

610 (21.3)

 Graduate or professional degree

 Pfizer-BioNTech

1217 (42.6)

Systemic rheumatic disease diagnosis†
 Rheumatoid arthritis

1209 (42.3)

 Inflammatory myositis

487 (17.0)

 Sjögren’s syndrome

438 (15.3)

 Systemic lupus erythematosus

391 (13.7)

 Spondyloarthritis, other than psoriatic arthritis

256 (9.0)

 Psoriatic arthritis

206 (7.2)

 Other connective tissue disease‡

196 (6.9)

 Systemic vasculitis

167 (5.8)

 Systemic sclerosis

126 (4.4)

 Antiphospholipid syndrome

68 (2.4)

 Autoinflammatory disease

31 (1.1)

 Sarcoidosis

21 (0.7)

Medications†
Systemic glucocorticoids

762 (26.6)

NSAIDs

740 (25.9)

DMARDs

1522 (53.2)

 Janssen/Johnson & Johnson

50 (1.7)

 Other vaccines‡‡

33 (1.2)

*Other participants include Pacific Islander, other, prefer not to say and do
not know/unsure.
†Participants may indicate more than one rheumatic disease and more
than one antirheumatic medication.
‡Other connective tissue disease include mixed connective tissue disease
and undifferentiated connective tissue disease.
§Includes apremilast, azathioprine, 6-mercaptopurine, leflunomide,
sulfasalazine.
¶Includes calcineurin inhibitors (ciclosporin, tacrolimus),
cyclophosphamide, thalidomide and lenalidomide.
**Includes asthma, emphysema, chronic bronchitis, chronic obstructive
pulmonary disease, pulmonary hypertension, interstitial lung disease,
idiopathic pulmonary fibrosis, other lung diseases.
††Includes belimumab, IL-1 inhibitors (anakinra, canakinumab, rilonacept),
IL-6 inhibitors (tocilizumab, sarilumab, siltuximab), IL-12/IL-23 inhibitors
(ustekinumab, guselkumab), IL-17 inhibitors (secukinumab, ixekizumab),
eculizumab, mepolizumab and vedolizumab.
‡‡Includes Novavax, Sinovac/Sinopharm, Sputnik V, Cansino, ‘not sure’
and ‘other’.
bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic
DMARDs; DMARDs, drug-modifying antirheumatic drugs; IL, interleukin;
IVIG, intravenous immunoglobulin; JAK, Janus kinase inhibitors; NSAIDs,
non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.

Continued
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Table 2 Communication with healthcare providers
regarding COVID-19 vaccination
Number of
respondents
N (%)
Contacted healthcare provider to discuss
vaccine

N=2860

 Yes

1775 (62.1)

 No

965 (33.7)

 Not sure/Not applicable

120 (4.2)

Contact from healthcare provider to
discuss vaccine

N=2860

 Yes

1349 (47.2)

 No

1383 (48.4)

 Not sure/Not applicable

128 (4.5)

Discussed vaccine with healthcare provider N=2860
during a visit
 Yes

1817 (63.5)

 No

932 (32.6)

 Not sure/Not applicable

111 (3.9)

Advice from healthcare provider about
receiving COVID-19 vaccine

N=2341

 Strongly endorsed

1938 (82.8)

 Suggested it
 Provider was unsure

300 (12.8)
42 (1.8)

 Advised against it

6 (0.3)

 Strongly discouraged

4 (0.2)

 Respondent unsure/Missing

51 (2.2)

Satisfaction about COVID-19 vaccine
conversation with healthcare provider

N=2341

 Very satisfied

1491 (63.7)

 Satisfied

574 (24.5)

 Neither satisfied nor dissatisfied

210 (9.0)

 Dissatisfied

52 (2.2)

 Very dissatisfied

14 (0.6)

reported contacting their healthcare provider to discuss
COVID-19 vaccination (1775, 62.1%), having the healthcare provider contact them (1349, 47.2%) and/or having
a discussion regarding vaccines during a clinical visit
(1817, 63.5%) (table 2). Of all respondents who discussed
vaccination with their healthcare provider, 2238/2341
(95.6%) reported that vaccination was recommended,
while 42 (1.8%) answered that their provider was unsure,
and 10 (0.4%) reported a provider recommendation
against vaccination. Most patients (2065, 88.2%) were
satisfied with the conversation with their clinician, while
only a minority were dissatisfied (66, 2.8%) or neither
satisfied nor dissatisfied (210, 9.0%).
Medications and COVID-19 vaccination
Most participants (1911, 66.8%) agreed with temporarily discontinuing their medications to improve
Sattui SE, et al. RMD Open 2021;7:e001814. doi:10.1136/rmdopen-2021-001814

Figure 2 Willingness to temporarily or permanently
discontinue medications when receiving the COVID-19
vaccine. IL, interleukin; NSAIDs, non-steroidal anti-
inflammatory drugs; csDMARDs, conventional synthetic
drug modifying antirheumatic drugs; JAK, Janus kinase
inhibitors; TNF, tumour necrosis factor; IVIG, intravenous
immunoglobulin. *Includes apremilast, azathioprine,
6-mercaptopurine, leflunomide and sulfasalazine.
†Includes calcineurin inhibitors (ciclosporin, tacrolimus),
cyclophosphamide, thalidomide and lenalidomide.
‡Includes belimumab, IL-1 inhibitors (anakinra,
canakimumab, rilonacept), IL-6 inhibitors (tocilizumab,
sarilumab, siltuximab), IL-12/IL-23 inhibitors (ustekinumab,
guselkumab), IL-17 inhibitors (secukinumab, ixekizumab),
eculizumab, mepolizumab and vedolizumab.

vaccine effectiveness, while 472 (16.5%) disagreed and
477 (16.7%) reported being unsure. Concern for flare
of systemic rheumatic disease after receiving the vaccine
was reported in 1267 (44.3%) respondents, while 1009
(35.3%) were not concerned, and 584 (20.4%) were
unsure.
When asked about the specific medications that participants reported taking for the treatment of their systemic
rheumatic disease, the majority were willing to discontinue these medications due to COVID-19 vaccination
(figure 2; online supplemental table). For participants
taking methotrexate, 700/855 (81.9%) were willing to
stop, with only 59 (6.9%) not willing to stop. For other
medications recommended by the ACR to be modified
around COVID-19 vaccination (eg, NSAIDs, mycophenolate, abatacept, rituximab, JAK inhibitors), the majority
of respondents were willing to discontinue temporarily.
Among participants taking systemic glucocorticoids,
fewer (375/762, 49.2%) were willing to stop, 246 (32.3%)
were not willing to stop and 141 (18.5%) were unsure.
Finally, when asked about actual medication discontinuation, most patients who reported taking any prescription medication (1875/2644, 70.9%) answered that they
did not temporarily stop or discontinue any of their
rheumatic medications before or after receiving the
COVID-19 vaccine, while a minority decided to change
their medication use (764, 28.9%). Only five (0.2%)
patients were not sure if they had made any changes to
their medication use.
Systemic rheumatic disease flare was the most frequently
reported concern regarding holding or stopping
5
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Table 3 Concerns about medication discontinuation around COVID-19 vaccination
Side effects
Withdrawal when previously
effects
stopped

Unsuccessful
Medication may
when previously no longer work No
stopped
as well
concerns

N

Disease
flare

Systemic
glucocorticoids

762

443 (58.1)

188 (24.7)

26 (3.4)

28 (3.7)

15 (2.0)

62 (8.1)

NSAIDs

740

412 (55.7)

18 (2.4)

29 (3.9)

13 (1.8)

14 (1.9)

254 (34.3)

Antimalarials

733

518 (70.7)

24 (3.3)

8 (1.1)

8 (1.1)

18 (2.5)

157 (21.4)

Methotrexate

855

616 (72.0)

13 (1.5)

10 (1.2)

3 (0.4)

39 (4.6)

174 (20.4)

Other csDMARDs*

513

372 (72.5)

13 (2.5)

6 (1.2)

8 (1.6)

19 (3.7)

95 (18.5)

Mycophenolate

228

169 (74.8)

8 (3.5)

9 (4.0)

2 (0.9)

7 (3.1)

33 (14.6)

Other
antimetabolites†

21

11 (52.4)

1 (4.8)

1 (4.8)

0 (0)

1 (4.8)

7 (33.3)

Abatacept

71

53 (74.6)

3 (4.2)

1 (1.4)

0 (0)

5 (7.0)

9 (12.7)

Rituximab

162

131 (81.9)

1 (0.6)

3 (1.9)

2 (1.3)

7 (4.4)

18 (11.3)

TNF inhibitors

493

369 (75.5)

6 (1.2)

5 (1.0)

4 (0.8)

73 (14.8)

36 (7.4)

Other biologics‡

206

157 (77.3)

4 (2.0)

2 (1.0)

3 (1.5)

21 (10.2)

19 (9.4)

JAK inhibitors

121

104 (86.0)

2 (1.7)

1 (0.8)

0 (0)

7 (5.8)

7 (5.8)

IVIG

102

80 (79.2)

2 (2.0)

1 (1.0)

1 (1.0)

1 (1.0)

17 (16.8)

*Includes apremilast, azathioprine, 6-mercaptopurine, leflunomide, sulfasalazine.
†Includes calcineurin inhibitors (ciclosporin, tacrolimus), cyclophosphamide, thalidomide and lenalidomide.
‡Includes belimumab, IL-1 inhibitors (anakinra, canakimumab, rilonacept), IL-6 inhibitors (tocilizumab, sarilumab, siltuximab), IL-12/IL-23
inhibitors (ustekinumab, guselkumab), IL-17 inhibitors (secukinumab, ixekizumab), eculizumab, mepolizumab and vedolizumab.
csDMARDs, conventional synthetic DMARDs; DMARDs, drug-modifying antirheumatic drugs; IL, interleukin; IVIG, intravenous
immunoglobulin; JAK, Janus kinase inhibitors; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.

antirheumatic medications (table 3). In participants taking
systemic glucocorticoids, disease flares were the most
frequently reported concern (443/762, 58.1%) followed by
withdrawal effects (188, 24.7%). Disease flare was the most
common concern among patients on all other medications.
‘No concerns’ was the second most frequent response for
people receiving all other medications, except for TNF
inhibitors and other bDMARDs where ‘concern for rheumatic medication may not work as well’ (73/494, 14.8% and
21/206, 10.2%, respectively) was reported.
COVID-19 vaccination-associated adverse events
Among all participants, 1371/2860 (47.9%) participants
reported at least one adverse event lasting for at least 2
days post-COVID-19 vaccine (table 4). Fatigue or sleepiness (955, 33.4%) was the most common reported adverse
event, followed by headache (792, 27.7%), and widespread muscle/joint pains (653, 22.8%). There were only
six (0.2%) episodes of self-reported anaphylaxis. Flares of
existing systemic rheumatic disease, lasting at least 2 days
post-COVID-19 vaccine, were reported by 382 (13.4%) of
participants, with 132 (4.6%) requiring a new or increased
dose of medication to treat the flare. The frequency of
adverse events and flares of disease were similar across
vaccine types.
DISCUSSION
This is the largest international survey of patient perceptions and outcomes related to COVID-19 vaccines among
6

vaccinated people with systemic rheumatic diseases.
Almost all participants who discussed vaccination with
a provider were recommended to receive a COVID-19
vaccination and respondents were overall satisfied with
COVID-19 vaccine-related conversations with their clinicians. The majority were willing to discontinue their
medications to improve vaccine response, although
many remained concerned about systemic rheumatic
disease flares. Although 1 in 8 reported a flare of disease
after vaccination, fewer than 1 in 20 required a change
in treatment. While these findings have been reassuring
regarding communication with physicians regarding
vaccination recommendations, individuals with systemic
rheumatic disease remain concerned about the side
effects of vaccines, and the risk of flares associated with
vaccination, particularly around holding antirheumatic
medications.
People with systemic rheumatic disease represent a
subgroup for whom general population data may not
apply. Potential concerns include reduced immunogenicity of vaccines related to either the underlying condition or the use of antirheumatic medications; and vaccines
causing worsened adverse events or flares of their underlying rheumatic diseases.2 In an international survey of
1531 individuals with rheumatic disease conducted in
December 2020, for instance, 32% reported uncertainty
around vaccination,3 which may in part be driven by
these concerns.
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Table 4 Adverse events and disease flares after COVID-19 vaccination, reported by patients to be severe and lasting at least
2 days
All
n=2860

Pfizer-BioNTech
n=1522

Oxford/AstraZeneca
n=645

Moderna
n=610

Janssen/Johnson & Others*
Johnson n=50
n=33

1350 (47.2)

648 (42.6)

335 (51.9)

327 (53.6)

30 (60.0)

10 (30.3)

Fatigue or sleepiness

955 (33.4)

455 (29.9)

229 (35.5)

245 (40.2)

22 (44.0)

4 (12.1)

Headache

792 (27.7)

350 (23.0)

218 (33.8)

196 (32.1)

23 (46.0)

5 (15.2)

Widespread muscle/Joint
pain

653 (22.8)

294 (19.3)

166 (25.7)

176 (28.9)

17 (34.0)

0 (0)

Fever or chills

568 (19.9)

214 (14.1)

167 (25.9)

170 (27.9)

Any adverse events

Anaphylaxis†

6 (0.2)

2 (0.1)

1 (0.2)

16 (32.0)

1 (3.0)

1 (0.2)

1 (2.0)

1 (3.0)

64 (10.5)

Other‡

204 (7.1)

86 (5.7)

49 (7.6)

4 (8.0)

1 (3.0)

Nausea or vomiting

364 (12.7)

167 (11.0)

90 (14.0)

101 (16.6)

6 (12.0)

0 (0)

Any flare of rheumatic
disease§

382 (13.4)

184 (12.1)

93 (14.4)

96 (15.7)

7 (14.0)

2 (6.1)

Flare requiring new
or increased dose of
medication§

132 (4.6)

58 (3.8)

40 (6.2)

32 (5.2)

2 (4.0)

0 (0)

*Includes Novavax, Sinovac/Sinopharm, Sputnik V, Cansino, not sure and others.
†Anaphylaxis was not required to last 2 days.
‡Including chest pain/palpitations, other allergic reactions and rash.
§Exacerbation of symptoms or new symptoms attributed to underlying systemic rheumatic disease.

Rheumatologists have a prominent role in communicating risks and benefits of vaccination. Prior surveys
of people with systemic rheumatic diseases have highlighted limited communication with rheumatologists or
other healthcare providers, especially about medication
changes.9–11 Other studies have cited lack of a recommendation from a treating physician for vaccination
hesitancy.12–15 Among the vaccinated population in our
study, there was a high frequency of communication with
clinicians about the COVID-19 vaccines, and respondents
were generally very satisfied. A key factor is the timing of
our survey during global vaccination efforts versus other
surveys that were completed prior to the availability of
the COVID-19 vaccine. Another factor is that our study
sample was limited to those who were vaccinated, so good
communication with healthcare providers over vaccine
recommendations is unsurprising.
Whether to hold antirheumatic medications for vaccination, and for how long, remains unclear for many
medication classes. Hypothetical concerns about reduced
immunogenicity have recently been corroborated by
antibody titre studies.16 17 Recommendations from the
ACR, for instance, have reflected these concerns. Initial
guidance in February of 2021 recommended holding
methotrexate, JAK inhibitors, abatacept and rituximab in
certain patients with controlled disease6; an April 2021
update also included mycophenolate mofetil.18 These
guidelines were based on limited data, including one
randomised controlled trial of methotrexate holding
for influenza vaccination in patients with RA,19 and
two studies of holding tofacitinib in patients with RA.20
Our survey found that most patients would be willing
to temporarily discontinue their medications but had
Sattui SE, et al. RMD Open 2021;7:e001814. doi:10.1136/rmdopen-2021-001814

concerns about a flare of their systemic rheumatic
disease. As expected, current glucocorticoid users had an
especially high frequency of respondents who were less
willing to hold these medications. This may be explained
by prior experience of flares when stopping or lowering
dose of glucocorticoids, concerns about adrenal insufficiency or a relationship between glucocorticoid use and
active disease. However, despite reported willingness,
only a minority of participants discontinued any medication around COVID-19 vaccination. Future studies
are needed to firmly establish an evidence base for
temporarily holding specific antirheumatic therapies to
enhance vaccine efficacy while balancing risk for disease
flare.
The degree to which vaccination in general and the
COVID-19 vaccinations in particular cause flares of rheumatic diseases has been a principal concern.21 Prior to the
COVID-19 pandemic, a study in the UK Clinical Practice
Research Database found no increased risk of flare after
influenza vaccination among people with autoimmune
inflammatory rheumatic disease.22 In a small study, RA
disease activity remained stable following hepatitis B vaccination.23 Conversely, an internet-
based case-
crossover
study of patients with confirmed gout found twofold
higher odds for gout flares after any patient-reported
vaccination.24 Similar to the rates reported in trials in
the general population, a minority of patients in our
study reported systemic reactions to vaccination, which
included fatigue, fever and pain. Systemic rheumatic
disease flares requiring a change in medication, however,
were uncommon. These data align with a large, physician-
reported registry supported by EULAR COVID-19 database.25 Between 5 February and 27 April 2021, clinicians
7
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reported 1519 patients with rheumatic disease who had
received COVID-19 vaccination, the majority (83%) of
whom received an mRNA-based vaccine. Overall, 31%
had potential vaccine-related side effects; 5% had flares
of their underlying systemic rheumatic disease, 1.2% of
which were reported as severe. In two prospective cohorts
of patients with systemic rheumatic disease followed
after COVID-19 vaccination, disease activity remained
stable.26 27 The complementary findings from these two
studies provide reassuring evidence regarding safety and
reactogenicity of COVID-19 vaccination among a systemic
rheumatic disease population.
Strengths of our study include rapid dissemination,
global reach and questions specifically addressing
concerns and willingness to hold specific antirheumatic
medications. Several important limitations should be
acknowledged. First, selection bias may have resulted
from respondents with adverse events being more likely to
fill out the survey. Despite this, the frequency of systemic
rheumatic disease flares requiring medication changes
remained low and was overall consistent with similar
registries. Second, although participants were asked “Has
a doctor ever told you had any of the following rheumatologic diseases?”, report of self-diagnosis or misdiagnosis
is a possibility. However, the reports of treatment with
systemic immunomodulators prescribed by clinicians
and the fact that the distribution of the survey through
patient organisations potentially minimises this making
it unlikely that this could substantially affect the results.
Third, this study was limited to English, Hebrew and
Italian translations of the survey and may not be generalisable to those who speak other languages or reside
in other regions. Translations into other languages are
ongoing and will be reported in the future. Fourth,
respondents were mostly white and reported high levels
of education. These results may not be applicable to
addressing barriers among other racial or ethnic groups
or among other socioeconomic groups.28–30 Fifth, at
the time of the survey, geographic variation in vaccine
availability and access resulted in a preponderance of
UK and US respondents. Sixth, the timing of our survey
coincided with the Centers for Disease Control and Food
and Drug Administration pause on the Janssen/Johnson
& Johnson vaccine,31–33 which limited the number of
responses from those who had received this vaccine.
Seventh, some conditions such as inflammatory myositis
may be over-represented in our cohort, due to the registries and patient advocacy groups to which our survey was
disseminated most easily. Finally, this was a descriptive
analysis and inferential statistics were intentionally not
performed.
CONCLUSION
This study presents encouraging data regarding communication between people with systemic rheumatic diseases
and their physicians and to the overall safety of COVID-19
vaccination in this patient population. Reassuringly,
8

significant flares requiring changes in medications were
relatively infrequent. Clinicians should maintain awareness of changing guidelines as further data become available to provide continued communication and patient
counselling regarding risks and benefits of vaccination.
Future studies should assess the degree to which vaccine
immunogenicity and reactogenicity among individuals
with systemic rheumatic disease differ compared with the
general population. Further knowledge about barriers to
vaccination in different racial and ethnic groups among
patients living with systemic rheumatic diseases is needed.
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